1. Home
  2. RVPH vs EQH Comparison

RVPH vs EQH Comparison

Compare RVPH & EQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • EQH
  • Stock Information
  • Founded
  • RVPH 2006
  • EQH 1859
  • Country
  • RVPH United States
  • EQH United States
  • Employees
  • RVPH N/A
  • EQH N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • EQH Specialty Insurers
  • Sector
  • RVPH Health Care
  • EQH Finance
  • Exchange
  • RVPH Nasdaq
  • EQH Nasdaq
  • Market Cap
  • RVPH 32.8M
  • EQH N/A
  • IPO Year
  • RVPH N/A
  • EQH N/A
  • Fundamental
  • Price
  • RVPH $0.39
  • EQH $51.85
  • Analyst Decision
  • RVPH Strong Buy
  • EQH Strong Buy
  • Analyst Count
  • RVPH 5
  • EQH 10
  • Target Price
  • RVPH $9.00
  • EQH $65.30
  • AVG Volume (30 Days)
  • RVPH 3.7M
  • EQH 2.7M
  • Earning Date
  • RVPH 08-13-2025
  • EQH 08-05-2025
  • Dividend Yield
  • RVPH N/A
  • EQH 2.07%
  • EPS Growth
  • RVPH N/A
  • EQH 13.70
  • EPS
  • RVPH N/A
  • EQH 3.76
  • Revenue
  • RVPH N/A
  • EQH $15,105,000,000.00
  • Revenue This Year
  • RVPH N/A
  • EQH $19.33
  • Revenue Next Year
  • RVPH N/A
  • EQH $0.28
  • P/E Ratio
  • RVPH N/A
  • EQH $13.89
  • Revenue Growth
  • RVPH N/A
  • EQH 45.39
  • 52 Week Low
  • RVPH $0.30
  • EQH $36.46
  • 52 Week High
  • RVPH $4.28
  • EQH $56.61
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 35.22
  • EQH 39.90
  • Support Level
  • RVPH $0.38
  • EQH $54.39
  • Resistance Level
  • RVPH $0.45
  • EQH $56.42
  • Average True Range (ATR)
  • RVPH 0.05
  • EQH 1.13
  • MACD
  • RVPH 0.01
  • EQH -0.41
  • Stochastic Oscillator
  • RVPH 17.57
  • EQH 0.21

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: